Key points are not available for this paper at this time.
For the successful development of live biotherapeutic products (LBPs), which are promising microbiome-based therapeutics, it is required to rigorously evaluate their quality, safety, and efficacy. To this end, we present a model-guided framework where genome-scale metabolic models (GEMs) can be exploited for characterizing LBP candidate strains and their metabolic interactions with adjacent microbiome and host cells at a systems level. In this perspective, we outline a GEM-based strategy for screening, assessment, and design of personalized multi-strain LBPs.
Lee et al. (Mon,) studied this question.